detailed results from the RELIEVE UCCD Phase 2b study of duvakitug (TEV’574/SAR447189) for moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD), the two most common forms of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback